A carregar...
Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval
Moxetumomab pasudotox (MP) is an immunotoxin that recently received US Food and Drug Administration (FDA) approval for the treatment of hairy cell leukemia (HCL) that has failed at least 2 prior lines of therapy, including a purine analog. MP is a recombinant immunotoxin that consists of an anti-CD2...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6784515/ https://ncbi.nlm.nih.gov/pubmed/31594764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000507 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|